Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30322% above fair value
$29.04−0.44 (-1.49%)
Close on Nov 13, 2026Market cap $4.63BP/E –Yield –
Adaptive Biotechnologies operating margin
Operating margin is operating income as a percentage of revenue.
Adaptive Biotechnologies's operating margin for the twelve months ending Sep 30, 2026 was -16.2%. For fiscal 2025 it was -20.6%, against -90.8% the year before. The highest annual figure on record is -20.6% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -20.6% | +70.2 |
| FY2024 | Dec 31, 2024 | -90.8% | +42.5 |
| FY2023 | Dec 31, 2023 | -133.3% | −25.3 |
| FY2022 | Dec 31, 2022 | -108.0% | +27.4 |
| FY2021 | Dec 31, 2021 | -135.4% | +19.9 |
| FY2020 | Dec 31, 2020 | -155.3% | −63.2 |
| FY2019 | Dec 31, 2019 | -92.1% | −2.8 |
| FY2018 | Dec 31, 2018 | -89.4% | +26.3 |
| FY2017 | Dec 31, 2017 | -115.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -0.5% | −11.5 |
| Q2 FY2026 | Jun 30, 2026 | -22.0% | +20.5 |
| Q1 FY2026 | Mar 31, 2026 | -27.1% | +29.4 |
| Q4 FY2025 | Dec 31, 2025 | -17.8% | +53.5 |
| Q3 FY2025 | Sep 30, 2025 | 10.9% | +81.2 |
| Q2 FY2025 | Jun 30, 2025 | -42.5% | +67.0 |
| Q1 FY2025 | Mar 31, 2025 | -56.4% | +60.0 |
| Q4 FY2024 | Dec 31, 2024 | -71.3% | +83.9 |
| Q3 FY2024 | Sep 30, 2024 | -70.3% | +64.1 |
| Q2 FY2024 | Jun 30, 2024 | -109.6% | −11.8 |
| Q1 FY2024 | Mar 31, 2024 | -116.5% | +35.5 |
| Q4 FY2023 | Dec 31, 2023 | -155.2% | −84.2 |
| Q3 FY2023 | Sep 30, 2023 | -134.4% | −39.4 |
| Q2 FY2023 | Jun 30, 2023 | -97.7% | +22.5 |
| Q1 FY2023 | Mar 31, 2023 | -151.9% | +11.4 |
| Q4 FY2022 | Dec 31, 2022 | -71.0% | +91.4 |
| Q3 FY2022 | Sep 30, 2022 | -95.0% | +47.7 |
| Q2 FY2022 | Jun 30, 2022 | -120.3% | +9.0 |
| Q1 FY2022 | Mar 31, 2022 | -163.3% | −55.9 |
| Q4 FY2021 | Dec 31, 2021 | -162.4% | −15.8 |
| Q3 FY2021 | Sep 30, 2021 | -142.7% | −1.8 |
| Q2 FY2021 | Jun 30, 2021 | -129.2% | +46.6 |
| Q1 FY2021 | Mar 31, 2021 | -107.4% | +58.2 |
| Q4 FY2020 | Dec 31, 2020 | -146.6% | −46.6 |
| Q3 FY2020 | Sep 30, 2020 | -140.9% | −71.6 |
| Q2 FY2020 | Jun 30, 2020 | -175.9% | −103.1 |
| Q1 FY2020 | Mar 31, 2020 | -165.6% | −7.3 |
| Q4 FY2019 | Dec 31, 2019 | -99.9% | −17.6 |
| Q3 FY2019 | Sep 30, 2019 | -69.3% | −16.0 |
| Q2 FY2019 | Jun 30, 2019 | -72.7% | +42.3 |
| Q1 FY2019 | Mar 31, 2019 | -158.3% | – |
| Q4 FY2018 | Dec 31, 2018 | -82.3% | – |
| Q3 FY2018 | Sep 30, 2018 | -53.3% | – |
| Q2 FY2018 | Jun 30, 2018 | -115.1% | – |
See a number that looks wrong?